Moreover, immune checkpoint inhibitor therapeutics, such as those targeting CTLA-4 and PD-1/PD-L1, have not yielded clinical benefits in AML patients with weakened immune function [28, 29]. This evidence concerns the gene PDCD1 and acute myeloid leukemia.